Call 1-844-EMPLICITI (1-844-367-5424) Call 1-844-EMPLICITI (1-844-367-5424)
BMS Access Support®

This site is intended for U.S. residents 18 years of age or older.

Call 1-844-EMPLICITI (1-844-367-5424)
BMS Access Support®

This site is intended for U.S. residents 18 years of age or older.

 

WHAT IS EMPLICITI® (elotuzumab)?

EMPLICITI is a prescription medicine used to treat multiple myeloma in combination with the medicines:

  • Revlimid® (lenalidomide) and dexamethasone in adults who have received one to three prior treatments for their multiple myeloma.
  • Pomalyst® (pomalidomide) and dexamethasone in adults who have received at least two prior treatments including Revlimid and a proteasome inhibitor.

It is not known if EMPLICITI is safe and effective in children.

EMPLICITI COST

 

Pricing Information

Like many patients, knowing what you may pay for treatment can be a major concern. That’s why
Bristol-Myers Squibb (BMS) is committed to helping you understand your out-of-pocket (OOP)
costs and possible resources that may help make them more affordable.


The list price for EMPLICITI* is $5,027 per infusion (every 2 weeks)
when taken with lenalidomide and dexamethasone and
$9,425 per infusion (every 4 weeks) when taken with
pomalidomide and dexamethasone. Most patients will pay less.


If you have commercial insurance:

You could pay $25 per infusion with
the BMS Oncology Co-pay Assistance
Program. Learn about this program.

If you have Medicare:

You could pay $0–$1,885 per infusion if you are receiving EMPLICITI as part of your treatment
(depending on your specific Medicare benefits). The OOP cost of more than 50% of infusions is
$25 or less.

If you have Medicare Part B, you may also have a supplemental insurance plan that will pay all
or part of your EMPLICITI costs. If you have Medicare Part C, there is an OOP maximum, and
what you will pay for EMPLICITI depends on your plan’s benefit design and the level of other
healthcare expenses you have during the year. Please check with your Medicare plan
administrator for further details.

If you have Medicaid:

You could pay $0 to $20 per infusion (depending on state plan). To find out if you qualify for
Medicaid, or to get more information about co-payments in your state, use this link to visit the
Medicaid website.

If you do not have insurance coverage:

If you do not have medical coverage or your insurance does not cover EMPLICITI, you may pay
the list price shown above. Patients without insurance are encouraged to call 1-844-EMPLICITI
(1-844-367-5424)(1-844-367-5424) to explore potential options.


For additional information, the
BMS Access Support® program
provides resources to
help
patients understand their
insurance coverage and find
information on sources of
financial
support.

As part of the BMS Access Support program, the BMS Oncology Co-Pay Assistance Program
may help eligible commercially insured patients pay only $25 per infusion. BMS will cover the
rest of the cost, up to $25,000 per year.

Please visit BMS Access Support, or call BMS Access Support at
1-800-861-00481-800-861-0048,
8 AM to 8 PM ET, Monday to Friday.

*As of January 2019. Assuming an average patient weight of 75 kg and not inclusive of cycle 1 and 2. The cost of
treatment may vary depending on patient weight.

The recommended dosage of EMPLICITI when used with Revlimid® (lenalidomide) and dexamethasone is
10 mg/kg administered intravenously every week for the first two cycles (28-day cycle) and every 2 weeks
thereafter. Treatment is continued until disease progression or unacceptable toxicity.

The recommended dosage of EMPLICITI when used with Pomalyst® (pomalidomide) and dexamethasone is
10 mg/kg administered intravenously every week for the first two cycles (28-day cycle). Starting at cycle 3
(28-day cycle), administer EMPLICITI 20 mg/kg intravenously every 4 weeks. Treatment is continued until
disease progression or unacceptable toxicity.

Important Facts About EMPLICITI® (elotuzumab)

EMPLICITI in combination with
Revlimid® (lenalidomide) and dexamethasone or in combination with Pomalyst® (pomalidomide) and dexamethasone may cause the following serious side effects:
Infusion reactions, infections, risk of developing new cancers (malignancies), and liver problems. There are also other serious risks associated with Revlimid and Pomalyst to females and males of reproductive potential, including possible serious birth defects or death of an unborn baby, and specific requirements regarding birth control, pregnancy testing and blood and/or sperm donation. For more information, please read the Important Facts throughout this website or by expanding this section. Your healthcare team will work with you to manage any side effects you may experience throughout your treatment with EMPLICITI.

This is a summary of important information that you need to know about EMPLICITI. Your healthcare team can work with you to help answer any questions you may have about EMPLICITI.

Keep this information in a safe place, so you can refer to it before and during your treatment. Look out for these icons as you read:

Talk to your healthcare teamCall a healthcare provider right awayHelpful information to remember
What is EMPLICITI?

EMPLICITI is a prescription medicine used with other medications to treat the following types of adult patients with multiple myeloma:

People who have received 1-3 prior treatments for their multiple myeloma may receive:

EMPLICITI
(elotuzumab)
  Revlimid®
(lenalidomide)
  dexamethasone

People who have received at least 2 prior treatments, including Revlimid and a proteasome inhibitor, may receive:

EMPLICITI
(elotuzumab)
  Pomalyst®
(pomalidomide)
  dexamethasone

Remember to read the safety information for the other medications you are receiving.

The safety and effectiveness of EMPLICITI have not been studied in children.

What are the possible side effects of EMPLICITI?

EMPLICITI may cause side effects, some of which can be serious. Your healthcare team will work with you to manage any side effects you may experience throughout your treatment with EMPLICITI.

Serious side effects

Infusion reactions can happen during your EMPLICITI infusion or within 24 hours after your infusion. Symptoms of an infusion reaction may include:

  • fever
  • chills
  • rash
  • chest pain
  • trouble breathing

  • dizziness
  • light-headedness

Before every EMPLICITI infusion, your healthcare team will give you medications to help lower your chances of having an infusion reaction. If you have an infusion reaction while receiving EMPLICITI, your healthcare provider will slow or stop your infusion and treat your reaction. If you have a severe infusion reaction, your healthcare provider may decide to stop all your EMPLICITI infusions.

Call your healthcare provider or get medical help right away if you have any of the above symptoms after your infusion with EMPLICITI.

Infections may occur in patients who receive EMPLICITI + Revlimid + dexamethasone or EMPLICITI + Pomalyst + dexamethasone and can be serious. Symptoms of an infection may include:

  • fever
  • flu-like symptoms
  • cough
  • shortness of breath
  • burning with urination
  • painful skin rash

Call a healthcare provider right away if you have any signs or symptoms of an infection.

Developing new cancers (malignancies) is a risk in patients who receive EMPLICITI with Revlimid + dexamethasone or EMPLICITI with Pomalyst + dexamethasone. Your healthcare provider will check you for new cancers during your treatment with EMPLICITI.

Talk to your healthcare team to learn more about your risk of developing new cancers if you receive EMPLICITI.

Liver problems may occur. Symptoms of liver problems include:

  • tiredness
  • weakness
  • loss of appetite
  • yellowing of your skin or eyes
  • color changes in your stools
  •  
  • confusion
  • swelling of the stomach area

Your healthcare provider will do blood tests to check your liver during your treatment with EMPLICITI.

Talk to your healthcare team if you have any signs or symptoms of liver problems.

The most common side effects

The most common side effects of EMPLICITI when used with Revlimid + dexamethasone include:

  • fatigue
  • diarrhea
  • fever
  • constipation
  • cough
  • numbness, weakness, tingling, or burning pain in your arms or legs
  • sore throat or runny nose
  • upper respiratory tract infection
  • decreased appetite
  • pneumonia

The most common side effects of EMPLICITI when used with Pomalyst + dexamethasone include:

  • constipation
  • high blood sugar

These are not all of the possible side effects of EMPLICITI.

Call your doctor for medical advice about side effects.

You can report any side effects you experience to the FDA by calling
1-800-FDA-1088.

What should I discuss with my healthcare team before starting EMPLICITI?

Talk to your healthcare team about all of your medical conditions, including if you have an infection.

Let your healthcare team know as soon as possible if you are pregnant, planning to become pregnant, breastfeeding, or planning to breastfeed. It is not known if EMPLICITI can harm an unborn baby. However, Revlimid and Pomalyst may cause birth defects or death of an unborn baby. It is not known if EMPLICITI passes into breastmilk. You should not breastfeed during treatment with EMPLICITI + Revlimid + dexamethasone or with EMPLICITI + Pomalyst + dexamethasone.

Before receiving EMPLICITI + Revlimid + dexamethasone, or EMPLICITI + Pomalyst + dexamethasone, females and males must agree to the instructions in the Revlimid REMS® program or the Pomalyst REMS® program, depending on which combination was prescribed for you. The programs have specific requirements about birth control (contraception), pregnancy testing, blood donation, and sperm donation that you need to know.

Talk to your healthcare team to learn more about Revlimid or Pomalyst.

Interactions with other drugs may affect the way EMPLICITI works in your body.

Talk to your healthcare team about all the medicines you take, including:

  • prescription medicines
  • over-the-counter medicines
  • vitamins
  • herbal supplements

Please read the Patient Information in the Full Prescribing Information.

689US1803829-03-01 04/19